安徽华人健康医药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 证券代码：301408 证券简称：华人健康 公告编号：2025-058 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议召开时间：2025 年 8 月 25 日（星期一）下午 14：30。 （2）网络投票时间：通过深圳证券交易所互联网系统投票的时间为 2025 年 8 月 25 日 9:15-15:00；通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 8 月 25 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。 2、现场会议召开地点：安徽省合肥市河北路 123 号华人健康总部 A1 栋 1501 会议室。 3、会议召开方式：本次会议采取现场投票和网络投票相结合的方式召开。 4、会议召集人：董事会。 5、会议主持人：董事长何家乐。 6、本次会议的召集、召开符合《中华人民共和国 ...

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

Group 1 - The core viewpoint of the news is that Huaren Health has seen a consistent inflow of financing over the recent trading days, indicating investor interest [1][2]. - On August 21, Huaren Health recorded a financing buy amount of 0.24 billion, ranking 2046 in the market, with a financing repayment amount of 0.19 billion, resulting in a net buy of 5.52 million [1]. - Over the three trading days from August 18 to August 21, Huaren Health received financing buys of 0.18 billion, 0.25 billion, and 0.24 billion respectively, showing a stable trend in financing activity [2]. Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold, indicating no activity in this area for Huaren Health [3].

8月20日，沪深两融数据显示，华人健康获融资买入额0.25亿元，居两市第1973位，当日融资偿还额0.19 亿元，净买入617.69万元。 最近三个交易日，15日-20日，华人健康分别获融资买入0.18亿元、0.18亿元、0.25亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 本文源自：金融界 作者：智投君 ...

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is engaged in pharmaceutical retail, agency, and terminal procurement, with a focus on traditional Chinese medicine, health products, medical devices, and innovative drugs. Group 1: Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and listed on March 1, 2023. The company is located in Hefei, Anhui Province [7] - The main business revenue composition includes: Western and Chinese medicine 80.25%, health products 4.62%, other goods 4.23%, medical devices 4.00%, Chinese medicine pieces 3.28%, specialty raw materials 1.89%, and others 1.72% [7] - As of March 31, 2025, the company had 18,000 shareholders, an increase of 9.39% from the previous period, with an average of 8,309 circulating shares per person, a decrease of 8.58% [8] Group 2: Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 1.267 billion yuan, a year-on-year increase of 14.71%, and a net profit attributable to shareholders of 61.22 million yuan, a year-on-year increase of 28.15% [8] - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [9] Group 3: Market Position and Strategy - The company has established a presence on major e-commerce platforms in China, including JD.com, Pinduoduo, and Meituan, in addition to Alibaba's Tmall and Ele.me [2] - The company is focusing on the integration of emerging technologies, particularly artificial intelligence, to enhance operational efficiency and customer experience [2][3] - The company’s subsidiary, Anhui Zhengyao Pharmaceutical Technology Co., Ltd., is dedicated to the research and development of innovative and high-end generic drugs, with 22 drugs under research as of June 30, 2023 [3] Group 4: Shareholder Structure and Investment - Alibaba Health, a subsidiary of Alibaba, holds 7.51% of the company's shares, indicating a strategic partnership with various Alibaba platforms [3] - The company has a diversified shareholder base, with no significant control by major shareholders, as indicated by the scattered distribution of shares [5]

从资金流向上来看，当日医药商业板块主力资金净流入4.72亿元，游资资金净流出2.9亿元，散户资金净 流出1.82亿元。医药商业板块个股资金流向见下表： 证券之星消息，8月19日医药商业板块较上一交易日上涨0.63%，塞力医疗领涨。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 31.40 | 5.12% | 61.67万 | | 19.77亿 | | 301408 | 华人健康 | 15.41 | 3.98% | 24.10万 | | 3.67亿 | | 301126 | 达嘉维康 | 13.24 | 3.36% | 19.13万 | | 2.54亿 | | 600538 | 国发股份 | 6.28 | 2.95% | 19.80万 | | 1.22亿 | | 603122 | 合富中国 | 7.25 | 2.55% | ...

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is experiencing growth in its business operations, particularly in the fields of pharmaceutical retail, agency, and terminal procurement, with a focus on integrating new technologies like AI to enhance service efficiency and customer experience [2][3]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and went public on March 1, 2023. The company is primarily engaged in pharmaceutical agency, retail, and terminal procurement [7]. - The main revenue composition includes: 80.25% from Chinese and Western medicines, 4.62% from health products, 4.23% from other goods, 4.00% from medical devices, 3.28% from traditional Chinese medicine pieces, 1.89% from specialty raw materials, and 1.72% from other supplementary products [7]. Financial Performance - For the period from January to March 2025, the company achieved a revenue of 1.267 billion yuan, representing a year-on-year growth of 14.71%. The net profit attributable to the parent company was 61.22 million yuan, reflecting a year-on-year increase of 28.15% [8]. Shareholder Structure - As of March 31, 2025, the number of shareholders reached 18,000, an increase of 9.39% compared to the previous period. The average circulating shares per person decreased by 8.58% to 8,309 shares [8]. Market Position and Trends - The company is positioned within the pharmaceutical and healthcare industry, specifically in the pharmaceutical retail sector, and is part of various concept sectors including pharmaceutical e-commerce, small-cap stocks, retail pharmacies, and innovative drugs [7]. - The company has established partnerships with major platforms such as Alibaba's Tmall and Ele.me, and is actively exploring AI technology applications in new retail collaborations to enhance operational efficiency and user engagement [2][3].

来源：新浪证券-红岸工作室 8月18日，华人健康涨0.34%，成交额1.87亿元。两融数据显示，当日华人健康获融资买入额1826.14万 元，融资偿还2758.57万元，融资净买入-932.43万元。截至8月18日，华人健康融资融券余额合计1.60亿 元。 融资方面，华人健康当日融资买入1826.14万元。当前融资余额1.60亿元，占流通市值的7.24%，融资余 额超过近一年90%分位水平，处于高位。 资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药80.25%，保健品4.62%，其他商品4.23%，医疗器械4.00%，中药饮片 3.28%，特色原料药1.89%，其他(补充)1.72%。 截至3月31日，华人健康股东户数1.80万，较上期增加9.39%；人均流通股8309股，较上期减少8.58%。 2025年1月-3月，华人健康实现营业收入12.67亿元，同比增长14.71%；归母净利润6122.23万元，同比增 长28.15%。 分 ...

Core Viewpoint - The trading activity of Huaren Health shows a mixed trend in financing and selling, indicating potential investor sentiment fluctuations in the stock. Group 1: Financing Activity - On August 18, Huaren Health received a financing buy amount of 0.18 billion, ranking 2367th in the market, with a financing repayment amount of 0.28 billion, resulting in a net sell of 9.32 million [1] - Over the last three trading days from August 14 to August 18, Huaren Health received financing buys of 0.37 billion, 0.18 billion, and 0.18 billion respectively [2] Group 2: Securities Lending - On the same day, the securities lending activity showed a sell of 0.00 thousand shares and a net buy of 0.01 thousand shares [3]

Core Insights - The latest stock price of Huaren Health is 14.77 yuan, reflecting a 1.79% increase from the previous trading day [1] - The stock reached a high of 14.80 yuan and a low of 14.47 yuan during the trading session, with a total transaction amount of 1.58 billion yuan [1] Company Overview - Huaren Health operates in the pharmaceutical commercial sector, with main business activities including drug retail, agency, and terminal procurement [1] - In 2024, retail business accounted for 69.47% of the company's total revenue, making it the primary source of income [1] Shareholder Activity - Shareholders Huangshan Saifu, Tengyuan Investment, Changqing Investment, and Suzhou Saifu have completed a share reduction plan, collectively reducing 5.3989 million shares, which represents 1.3497% of the company's total share capital [1] - The reduction was executed through centralized bidding and block trading methods [1] Capital Flow - On the day of reporting, the net outflow of main funds was 1.3614 million yuan, with a cumulative net outflow of 49.8052 million yuan over the past five trading days [1]